Board of Directors

DR. JOAN FALLON

Founder and CEO

Dr. Fallon began her research on Autism and related disorders over 20 years ago and founded Curemark as a platform to develop product candidates to address her findings. Dr. Fallon has both clinical expertise and academic experience—the former from running a private practice specializing in pediatric development, and the latter as an Assistant Professor of Natural Sciences and Mathematics at Yeshiva University.

Dr. Fallon has played an integral role in two very successful (and unprecedented) medical ventures. She was an Oxford Health Plans board member and helped achieve underwriting authority from New York State, for alternative and complementary medicine where none had yet existed. She also helped implement a cost-effective, interdisciplinary health plan for Oxford that increased the level of quality care for all children enrolled there. Dr. Fallon has written numerous scholarly articles, lectured around the world on developmental problems in the pediatric population and served on the Board of Directors of the ICA and Kentuckiana Children’s Center. She serves as a Senior Advisor to the Henry Crown Fellows at The Aspen Institute, as well as a Distinguished Fellow at the Athena Center for Leadership Studies at Barnard College/Columbia University. She is also a member of the Board of Trustees of Franklin & Marshall College. Dr. Fallon holds a B.A. degree from Franklin and Marshall College, a DC degree from Palmer University, and has completed the coursework for the MSc in clinical investigation from Harvard University’s joint program with Massachusetts General Hospital.

KIMBELL DUNCAN

Mr. Duncan is an investment professional with over 30 years’ experience in trading, principal transactions and early-stage venture investing.  He began his career as a trader at Goldman Sachs in 1987, moving to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities.  He has been an active angel investor since 2006, focusing on equity investments in promising, early-stage biotechnology companies, including Infirst Healthcare Limited, Pharmajet Ltd, Peptcell Limited and Curemark LLC.  He sits on the board of each of his portfolio companies.  He co-founded Rush Foundation in 2010, a charity focused on funding innovative solutions in the fight against the HIV pandemic in sub-Saharan Africa.  Kim holds a BS in Electrical and Electronics Engineering from Yale University, a MS in Biotechnology from Georgetown University and is currently a candidate for PhD in Pharmacology and Physiology from Georgetown University.

LEIGH MORGAN

Ms. Morgan brings to the board a wealth of leadership that spans the corporate, public, philanthropic, and higher education sectors. She served as the COO of the Bill and Melinda Gates Foundation, and Vice President/Global Head of HR Products at Genentech/Roche biopharma. She has served as Associate Chancellor at the University of California San Francisco (UCSF) and currently is the Vice Chair of the Board of the Fred Hutchinson Cancer Research Center in Seattle and a board member of the Fuqua School of Business Center for Advancement of Social Entrepreneurship at Duke University.

AFIA ASAMOAH

Afia is currently Head of Legal and People for Waymark, Inc., a health technology start-up providing community-based, tech-enabled healthcare services to individuals with Medicaid benefits.  Afia is a member of the senior management team, guiding strategy, managing risk, and growing and scaling the business in markets across the United States. Prior to joining Waymark, Afia spent 8 years at Google/Alphabet, leading and working with teams working on health technology, most recently in the role of Head of Legal for Google Health. Afia is a healthcare regulatory lawyer, with a degree in health policy from Harvard, and before moving to California, served as a Special Assistant in the Commissioner’s office of FDA and as an associate at a global law firm.